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Purpose: Recently, arginine vasopressin (AVP) has been revealed to have diverse functional roles in nervous tissues
beyond that of a vasoconstrictor. Several previous studies have indicated the existence of AVP in the retina, but the source
of AVP has not been determined. The objective of the present study was to address the question of whether retinal cells
have the ability to synthesize endogenous AVP to act in a paracrine or autocrine manner.
Methods:  We  used  AVP-eGFP  transgenic  rats  to  find  endogenous  AVP-positive  cells  in  the  retina  by
immunohistochemistry with an AVP antibody and a GFP antibody. We also examined AVP mRNA and AVP receptor
genes by reverse transcriptase (RT)–PCR of dissociated GFP-positive cells and whole retinas.
Results: Endogenous AVP-positive cells were found in the ganglion cell layer and inner nuclear layer of the retina of
AVP-eGFP transgenic rats by immunohistochemistry. As indicated by the results of RT–PCR of dissociated GFP-positive
cells, these cells have the ability to synthesize endogenous AVP, as well as transgenic AVP-eGFP. In addition, the V1a
and V1b AVP receptors were found in the wild-type rat retina by whole retina RT–PCR, but the V2 receptor was not
detectable. In dissociated AVP-eGFP-positive cells, no AVP receptor was detected by RT–PCR. Moreover, AVP secretion
was not detected by stimulation with a high potassium (50 mM) solution.
Conclusions: In the rat retina, we found retinal cells that have the ability to synthesize endogenous AVP, and that the
retina possesses V1a and V1b AVP receptors. Taken together, these results suggest that the retina has an intrinsic AVP-
synthesizing and -receiving mechanism that can operate in a paracrine manner via V1a and V1b receptors.
Arginine vasopressin (AVP) is a neuropeptide hormone
released from the dorsomedial suprachiasmatic nucleus to
regulate the homeostasis of osmolarity and the volume of body
fluids [1].  AVP  exerts  its  physiological  effects  through  the
V1a,  V1b,  and  V2 receptors  [2];  it is a potent stimulator of
vascular smooth muscle contraction  through V1a receptors,
with a specific intracellular  second  messenger  system [3].
AVP has an  important  role  in the maintenance  of  cardio-
vascular homeostasis  through these distinct receptors, which
are  potent  therapeutic  targets  for  the  treatment of heart
failure and the regulation of blood pressure [4,5].
Recently,  roles  of  AVP  other  than  its  role  as  a
vasoconstrictor have been revealed. AVP-positive cells were
discovered in the olfactory bulb, and were shown to be related
to  olfactory  function  and  social  recognition  rather  than
vasoconstriction [6]. Vasopressin is now known to be a key
factor of social recognition in the brain [7]. In fact, AVP-
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receptor V1a knockout mice showed impairment of social
recognition [8]. In the hypothalamus of the rat brain, AVP
regulates the cell volume of AVP-positive cells in an autocrine
manner [9].
Although several studies have indicated the presence of
AVP in the retina [10-12], little is known about the source and
function of retinal AVP. Djeridane [10] reported that AVP
was detected by immunohistochemistry in the retinal ganglion
cell layer (GCL), although Djeridane suggested that AVP
itself  is  not  synthesized  in  retinal  cells.  Palm  et  al.  [12]
reported that AVP was clearly present in the eye, but that it
might  be  stored  after  accumulation  from  blood  or
cerebrospinal fluid, or possibly produced locally. In regard to
the function in the eye, AVP was primarily thought to have
vasoactive/vascular effects on the endothelium to regulate
blood  flow  [13,14].  In  addition  to  its  vasoactive/vascular
effects,  AVP  may  have  a  pathological  role  in  regulating
intraocular pressure via the vasopressin V1 receptor [15]. It
was also reported that the human retinal pigment epithelium
in culture possesses the vasopressin V1 receptor [16]. The
remaining questions are whether AVP itself is synthesized in
the retina or whether it just comes from extraretinal brain
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3254tissue through blood vessels, as well as whether AVP acts on
the retina in a paracrine or autocrine manner.
The objective of the present study was to address the
question of whether retinal cells have the ability to synthesize
endogenous  AVP.  To  answer  this  question,  we  examined
AVP-enhanced green fluorescent protein (eGFP) transgenic
rats  to  find  endogenous  AVP-positive  retinal  cells  by
immunohistochemistry with an AVP antibody and a GFP
antibody, and by reverse transcriptase (RT)–PCR. AVP-eGFP
transgenic rats were designed to express AVP-eGFP in AVP-
secreting cells under the control of the AVP promoter [17].
We found that there were AVP-positive cells in both the inner
nuclear layer (INL) and GCL of the rat retina. In addition, the
V1a  and  V1b  AVP  receptors  were  found  in  the  retina.
Although the level of endogenous AVP expression was quite
low,  we  suggest  that  the  retina  has  an  intrinsic  AVP-
synthesizing and -receiving mechanism that can operate in a
paracrine manner.
METHODS
The arginine vasopressin–eGFP transgenic rat: Wild-type
male Wistar rats (Charles River Laboratories, Yokohama,
Japan)  and  heterozygous  transgenic  male  Wistar  rats  that
express an AVP-eGFP fusion gene [17] were bred and housed
under standardized conditions (12 h:12 h light-dark cycle)
with food and water. Five- to 12-week-old wild-type and
AVP-eGFP transgenic rats were used for experiments. Light-
adapted rats were deeply anesthetized with halothane (Takeda
Pharmaceutical,  Osaka,  Japan)  and  sodium  pentobarbital
(Dainippon  Pharmaceutical,  Osaka,  Japan),  and  then
sacrificed by decapitation. Eyes were removed, transferred to
carboxygenated Ames’ medium (Sigma-Aldrich, St. Louis,
MO), and hemisected, and then the retinas were teased off the
pigment epithelium. All procedures involving animals were
approved in advance by the Ethics Review Committee for
Animal  Experimentation  of  the  National  Institute  for
Physiological  Sciences,  and  were    in    accordance    with   the
guidelines of the Physiological Society of Japan.
Immunostaining: The isolated retinas were fixed in phosphate
buffered  saline  (PBS),  pH  7.4,  containing  4%
paraformaldehyde for 1 h at room temperature. The retinal
preparations were rinsed with PBS and incubated for 1 h at
4 °C in PBS with 4% donkey serum (Biowest, Nuaillé, France)
and 0.3% Triton X-100 (Katayama Chemical, Osaka, Japan)
for  blocking  before  the  addition  of  primary  antibodies.
Primary antibodies against AVP (1:800, rabbit polyclonal;
Calbiochem,  Darmstadt,  Germany)  and  GFP  (1:500,  goat
polyclonal; Rockland Immunochemicals, Gilbertsville, PA)
were  used.  The  preparations  were  incubated  in  primary
antibody solution for at least 4 days at 4 °C (whole mounts).
After several rinses in PBS, preparations were incubated with
secondary antibodies (donkey antirabbit IgG coupled to Alexa
Fluor 594 or donkey antigoat IgG coupled to Alexa Fluor 488,
from Invitrogen) diluted 1:1,000 in blocking buffer overnight
at  4  °C,  rinsed,  and  coverslipped  with  Fluoromount-G
(SouthernBiotech, Birmingham, AL). Images were captured
using  confocal  laser  scanning  microscopy  (A1R;  Nikon).
Nikon  PlanApo  VC20X  and  40X  lenses  were  used.  The
brightness and contrast of the images were adjusted by using
ImageJ  (National  Institutes  of  Health,  Bethesda,  MD)  or
Photoshop CS (Adobe, San Jose, CA).
Density recovery profile: The spacing of cell bodies of AVP-
eGFP-positive cells in the INL and the GCL (Figure 1) was
analyzed using the density recovery profile (DRP) method,
calculated in MatLab (The Mathworks, Lowell, MA) [18].
The  concept  of  DRP  analysis  used  the  spatial
autocorrelogram, as described previously [19].
Dissociation  of  GFP-positive  cells  from  the  arginine
vasopressin–eGFP  transgenic  rat  retina:  Small  pieces  of
retinas were cut off and dissociated in oxygenized 5 mM
HEPES Hank’s balanced salt solution (HBSS; Invitrogen,
Carlsbad,  CA),  pH  7.4,  containing  15.6  U/ml  papain
(Worthington,  Lakewood,  NJ)  and  12.5  μg/ml  L-cysteine
(Sigma-Aldrich) for 10 min at 37 °C. The retina pieces were
washed once with 5 mM HEPES HBSS containing 200 U/ml
DNase I (Sigma-Aldrich) and four times with 5 mM HEPES
HBSS, and then stored in 5 mM HEPES HBSS bubbled with
100% O2 at room temperature. The cells were dissociated by
mechanical  trituration  through  a  Pasteur  pipette.  GFP
expression was confirmed each time under a fluorescence
microscope (TE300; Nikon, Tokyo, Japan).
Reverse transcriptase–polymerase chain reaction from GFP-
positive cells: The techniques used were identical to those
previously  described  [9,20].  Using  a  RNeasy  Micro  Kit
(Qiagen, Hilden, Germany), we extracted total cellular RNA
from cytosol suctioned into gigasealed patch pipettes from 20
eGFP-positive cells and pooled them. RNA samples were
reverse-transcribed  with  random  6-mer  primers  using  a
PrimeScript 1st strand cDNA Synthesis kit (Takara Bio, Otsu,
Japan) according to the manufacturer’s protocol. PCR was
performed with 1 U of Blend Taq DNA polymerase (Toyobo,
Osaka, Japan) in a 40 μl reaction mix contained 1× buffer,
0.2 mM deoxynucleotide triphosphates (dNTPs), and 3 μl
cDNA template. Primer sequences are shown in Table 1. Note
that  we  used  two  different  pairs  of  primers  to  detect
endogenous AVP in experiments for which the results are
shown in Figure 2 and Figure 3. Amplification was performed
in a thermal cycler (GeneAmp PCR System 9700; Applied
Biosystems, Foster City, CA) under the following conditions:
initial heating at 94 °C for 2 min followed by 45 cycles of
denaturation at 94 °C for 30 s, annealing at 60 °C for 30 s,
extension at 72 °C for 1 min, and then final extension at 72 °C
for 5 min for endogenous AVP and transgene products of
AVP-eGFP; and initial heating at 94 °C for 2 min followed by
35 cycles of denaturation at 94 °C for 30 s, annealing at 60 °C
for 30 s, extension at 72 °C for 30 s, and then final extension
at  72  °C  for  5  min  for  glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as a positive control.
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reaction: Using TRIzol Reagent (Invitrogen), total RNA was
extracted from the retinas of six-week-old male Wistar rats
(Charles River Laboratories). RNA samples were treated with
Recombinant DNase I (RNase-free; Takara Bio) and reverse-
transcribed with oligo-dT primers using Superscript III RT
Figure 1. Endogenous arginine vasopressin–positive cells in the arginine vasopressin–eGFP transgenic rat retina. Arginine vasopressin (AVP)/
eGFP-positive cells in (A-C) the ganglion cell layer (GCL) and (D-F) inner nuclear layer (INL) of the AVP-eGFP transgenic rat retina in a
whole-mount preparation. A: AVP-eGFP expression in the GCL under a fluorescence microscope. B: A cell with GFP in the GCL detected
by a confocal microscope. C: The GFP-positive cell in B was also positive for AVP. D: AVP-eGFP  expression in the INL  under a fluorescence
microscope. E: Cells with GFP in the INL, detected by a confocal microscope. There are two distinct types of GFP-positive cells: brighter
cells and faint cells. Asterisks show faint cells. F: The brighter GFP-positive cell in E was also positive for AVP.  The scale bars  in A  and
D are 50 μm. The scale bars in B, C, E, and F are 10 μm. G: Density recovery profile (DRP) of GFP-positive cells in the GCL and brighter
GFP-positive cells in the INL (n=7 retina pieces). Error bars indicate standard error of the mean (SEM).
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AVP PCR primers designed by Glasgow et al. [21], V1a and
GAPDH PCR primers designed by Sato et al. [9], and V2/a
Rho GTPase-activating protein 4 (ARHGAP4) PCR primers
designed by Vargas et al. [22] were employed. V1b PCR
primers were designed with Primer3 software. The sequences
of the primers are listed in Table 1. PCR was performed with
Blend Taq DNA polymerase (Toyobo) under the following
conditions: initial heating at 94 °C for 2 min followed by 25
cycles (GAPDH), 35 cycles (AVP, V1a, and V2/ARHGAP4),
or 40 cycles (V1b) of denaturation at 94 °C for 30 s, annealing
at 60 °C for 30 s, extension at 72 °C for 30 s, and then final
extension at 72 °C for 5 min. The products of RT–PCR were
electrophoresed on a 2% agarose gel, the bands were excised,
and then the products were cloned into the pGEM-T Easy
vector (Promega, Madison, WI) after purification with the
Wizard  SV  Gel  and  PCR  Clean-Up  System  (Promega).
Plasmids were extracted with PI-200 (Kurabo, Osaka, Japan),
treated with RNase (DNase free) Glycerol Solution (Nippon
Gene,  Tokyo,  Japan),  purified  by  phenol-chloroform
extraction and ethanol precipitation, and used as templates for
sequencing  using  a  Big-Dye  Terminator  v3.1  Cycle
Sequencing Kit (Applied Biosystems) and an ABI PRISM 310
Genetic Analyzer (Applied Biosystems).
Measurements of arginine vasopressin secretion: The amount
of AVP secretion from whole retinas or dissociated retinal
cells exposed to control solution or high potassium (50 mM)
solution was measured at room temperature using an arg8-
Vasopressin Enzyme Immunoassay Kit (Assay Designs, Ann
Arbor, MI) according to the manufacturer’s protocol. The
control solution contained (in mM): 125 NaCl, 2.5 KCl, 2
CaCl2, 1 MgCl2, 26 NaHCO3, 1.25 KH2PO4, and 12 glucose
(pH 7.4; 300 mosmol/kg-H2O). The high potassium (50 mM)
solution contained (in mM): 77.5 NaCl, 50 KCl, 2 CaCl2, 1
MgCl2, 26 NaHCO3, 1.25 KH2PO4, and 12 glucose (pH 7.4;
300 mosmol/kg-H2O).
For the measurements, whole retinas were isolated from
four 5-week-old male wild-type Wistar rats (Charles River
Laboratories).  Then  whole  retinas  were  put  in  a
carboxygenated  custom-made  chamber.  After  1.5  h  of
preincubation in the control solution, retinas were rinsed once
in the control solution and then each retina was incubated for
15 or 30 min in 5 ml control solution or high potassium
(50  mM)  solution.  Each  time,  0.5  ml  was  sampled  for
measurements.
Dissociation of retinal cells was performed using two
retinas  of  a  two-month-old  wild-type  Wistar  rat  (Charles
River  Laboratories),  similar  to  the  procedure  for  the
dissociation of the AVP-eGFP transgenic rat retina in this
study. After a 20 min preincubation of a batch of dissociated
cells, the cells were incubated for 5, 15, or 30 min in the
control solution or the high potassium (50 mM) solution.
These solutions were then centrifuged at 500× g for 5 min at
4 °C and the supernatants were used for measurements.
Extraction of AVP was performed by application onto a
C-18  SEP-COLUMN  (Phoenix  Pharmaceuticals,
TABLE 1. RT–PCR PRIMER SEQUENCES.
mRNA species Sequence RT–PCR product
(bp)
Accession number Reference1
Endogenous AVP (in Figure 2)
AVP-F CCTCACCTCTGCCTGCTACTT 430 NM_016992.2  
AVP-R2 AGAATCCACGGACTCTTGTGT      
AVP-eGFP
AVP-F CCTCACCTCTGCCTGCTACTT 843    
AVP-eGFP-R ATGATATAGACGTTGTGGCTGTTGT      
GAPDH
GAPDH-F CATGCCGCCTGGAGAAACCTGCCA 429 NM_017008.3 [9]
GAPDH-R GGGCTCCCCAGGCCCCTCCTGTTG      
AVP (in Figure 3)
AVP-F CCTCACCTCTGCCTGCTACTT 463 NM_016992.2 [21]
AVP-R GGGGGCGATGGCTCAGTAGAC      
V1a receptor
V1a-F CGCAACATCCGCGGAAAGAC 484 NM_053019.2 [9]
V1a-R TCCACATCCCAGTGCTGTTC      
V1b receptor
V1b F CAGCCAGTCTACCTACCCTCTCA 335 NM_017205.2  
V1b R CCCTCGTGGCTGCAGAAGAT      
V2 receptor/ARHGAP42
V2/ARHGAP4-F CGTGGGATCCGGAAGCTCCTCTGG 301 (V2 receptor) NM_019136.1 [22]
V2/ARHGAP4-R TCAGGGCCAACCCTAGATAGTCAG 462 (ARHGAP4) AY742900.1  
        1Published paper that RT–PCR primers have been already designed and used. 2ARHGAP4 gene overlaps V2 receptor gene and
      is expressed from the opposite DNA strand of the V2 receptor gene in rat tissues [24].
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3257Burlingame, CA) according to the manufacturer’s protocol
using Buffers A and B (Phoenix Pharmaceuticals). Extracted
AVP was dried with a vacuum freeze dryer (VD-800F; Taitec,
Koshigaya, Japan). The amount of AVP was estimated with a
Microplate reader (Multiscan MS-UV; Labsystems, Vienna,
VA) at a wavelength of 414 nm. The concentration of AVP
was  estimated  each  time  under  the  condition  that  the
concentration was set to 0 in the solution before incubation of
whole retinas.
RESULTS
Endogenous  arginine  vasopressin–positive  cells  in  the
arginine vasopressin–eGFP transgenic rat retina: The AVP-
eGFP transgenic rat was designed to express AVP-eGFP to
recapitulate  the  expression  of  endogenous  AVP  in  AVP-
secreting cells under control of the AVP promoter [17]. In the
transgenic  rat,  the  AVP-eGFP  fusion  gene  was  expressed
under the AVP promoter in cells that had endogenous AVP
promoter  activity  [6,17].  In  the  retina  of  the  AVP-eGFP
transgenic rat, AVP-eGFP-positive cells were identified in the
retinal GCL and the INL by immunoreactivity to the GFP
Figure  2.  Endogenous  arginine
vasopressin  mRNA  was  detected  by
reverse transcriptase–polymerase chain
reaction from dissociated GFP-positive
cells  and  the  whole  retina.  A:
Dissociation of the arginine vasopressin
(AVP)-eGFP  transgenic  rat  retina.
Under a fluorescence microscope, we
identified AVP-eGFP-positive cells by
GFP fluorescence. Scale bars are 20 μm.
B:  Reverse  transcriptase  (RT)–PCR
from  a  set  of  20  dissociated  GFP-
positive cells. A faint endogenous AVP
band (white arrow) and an AVP-eGFP
band  were  detected  by  the  indicated
primer pairs (Table 1) after 45 cycles of
RT–PCR. C: RT–PCR from the wild-
type whole retina. An endogenous AVP
band was also detected.
Figure  3.  Arginine  vasopressin
receptors  in  the  retina  detected  by
whole-retina  reverse  transcriptase–
polymerase chain reaction. A: Arginine
vasopressin  (AVP)  receptors  were
detected  from  a  whole  wild-type  rat
retina  by  reverse  transcriptase  (RT)–
PCR  with  the  indicated  primer  pairs
(Table 1). V1a and V1b receptors were
detected.  A  V2/ARHGAP4  band  was
also  detected,  but  by  cloning  and
sequencing  the  RT–PCR  product,  we
concluded that the V2/ARHGAP4 was
from  the  ARHGAP4  gene,  which
overlaps the V2 receptor gene and is
expressed  from  the  opposite  DNA
strand of the V2 receptor gene. B: No
AVP receptor was detected by RT–PCR
in  dissociated  AVP-eGFP-positive
cells, as shown in Figure 2B.
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3258antibody (Figure 1A,D). All of the GFP-positive cells in the
GCL were also immunoreactive to the AVP antibody (Figure
1B,C), although only 5% of the GFP-positive cells in the INL
were costained with the AVP antibody (Figure 1E,F). In the
INL,  there  were  two  distinct  types  of  GFP-positive  cells:
brighter cells and faint cells (Figure 1E, asterisks on faint
cells). Almost all of the brighter GFP-positive cells in the INL
were costained with an AVP antibody, although faint cells
were not. The number of AVP-eGFP-positive cells in the GCL
was 67.6 ±12.5 cells/mm2 (mean±standard error of the mean
[SEM], n=7 retina pieces). In the INL, the number of brighter
AVP-eGFP-positive cells was 76.4±7.0 cells/mm2 and the
number of faint GFP-positive cells was 1,500±84 cells/mm2.
The DRP of GFP-positive cells in the GCL and brighter cells
in the INL showed a mosaic distribution with a space size of
~50 μm (Figure 1G).
AVP-eGFP-positive  cells  in  the  GCL  had  no  GFP-
positive neurites/axons in the optical nerve layer identified by
GFP immunoreactivity. In addition, the diameter of the soma
of AVP-eGFP-positive cells in GCL was about 8 μm, similar
to that of the brighter cells in the INL. Although some retinal
ganglion cells can have somas of only ~11 μm diameter [23],
small soma size is another good indication that these are a
subtype of amacrine cells. Taken together, the results indicate
that brighter AVP-eGFP-positive cells in both the GCL and
INL are probably a subtype of amacrine cells with endogenous
AVP.
Endogenous arginine vasopressin mRNA in dissociated GFP-
positive  cells:  The  next  question  is  whether  AVP-eGFP-
positive cells have the ability to synthesize endogenous AVP.
We assessed the endogenous AVP–synthesizing ability by
RT–PCR from dissociated GFP-positive cells (Figure 2). We
dissociated  the  transgenic  rat  retina  enzymatically  and
collected the cytosol from brighter GFP-positive cells under
a  fluorescence  microscope  using  Microglass  pipettes  (see
Methods) [9]. RT–PCR was conducted to detect the transgene
mRNA of AVP-eGFP and the endogenous AVP mRNA with
primer pairs shown in Table 1 from a set of 20 GFP-positive
cells  [9,20].  After  45  cycles  of  RT–PCR,  we  found  an
endogenous AVP mRNA band, as well as a transgenic AVP-
eGFP mRNA band (Figure 2B). To confirm that the wild-type
retina  has  the  ability  to  synthesize  AVP,  we  checked  the
AVP mRNA expression in the wild-type whole retina. An
endogenous AVP band was also detected in the wild-type
retina (Figure 2C). Overall, AVP-eGFP-positive retinal cells
have the ability to synthesize endogenous AVP.
Arginine vasopressin receptors in the whole retina: Next, we
examined the possibility that AVP acts on the retina in a
paracrine or autocrine manner. If the AVP peptide itself is
synthesized and released from the retina to act on retinal cells,
there should be AVP receptors in the retina. We examined the
AVP receptor mRNA from the wild-type rat whole retina by
RT–PCR (Figure 3). The whole-retina RT–PCR indicated that
the retina has V1a and V1b AVP receptors. In regard to V2
receptors, our primer pairs could detect both the V2 receptor
gene  (301  base  pairs)  and  opposite  DNA  strand  of  the
ARHGAP4 gene, a Rho GTPase-activating protein 4 gene
(462 bp) [24] that overlaps the V2 receptor gene in the rat
(Figure 3, V2/ARHGAP4 lane). However, a V2 band could be
distinguished by its size from an ARHGAP4 band. In addition,
by  cloning  and  sequencing  the  RT–PCR  product,  we
concluded that the V2/ARHGAP4 band in Figure 3 was a band
of  ARHGAP4,  not  the  V2  receptor.  In  contrast,  no  AVP
receptor was detected by RT–PCR in dissociated AVP-eGFP-
positive  cells  (Figure  3B,  data  from  the  same  dissociated
AVP-eGFP-positive  cells  shown  in  Figure  2B).  Taken
together,  we  concluded  that  the  retina  has  an  AVP-
synthesizing and -receiving mechanism that can operate in a
paracrine, not autocrine, manner through V1a and V1b AVP
receptors.
Figure  4.  Arginine  vasopressin  secretion  was  not  detected  by
stimulation with high potassium solution. The arginine vasopressin
(AVP) concentration was assayed at 0 min (before stimulation), 15
min, and 30 min after the retina pieces were incubated in the control
solution or the high potassium (50 mM) solution (see Methods). The
concentration of AVP at each time was estimated under the condition
that the concentration was set to 0 in the solution before incubation
of the retina. The delta (Δ) AVP concentration shown here is defined
as the difference between the concentration of AVP each time and
the concentration before the incubation. No significant differences
were found (one-way ANOVA with Tukey’s post hoc test). Error
bars indicate standard error of the mean (SEM).
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3259Arginine  vasopressin  secretion  was  not  detected  by
stimulation  with  high  potassium  solution:  The  remaining
question is whether endogenous AVP is actually secreted in
the  retina  under  physiological conditions.  To   answer  this
question, we investigated endogenous AVP release from the
retina  by  stimulating  isolated  wild-type  retinas  with  high
potassium solution, which has been shown to stimulate AVP
release in the hypothalamus of the brain [25]. Isolated retinas
were rinsed once in the control solution, and then each retina
was incubated for 15 or 30 min in the control solution or the
high potassium (50 mM) solution. The AVP concentration
was assayed each time. Unfortunately, AVP levels were too
low to detect AVP secretion from the retina by stimulation
with the high potassium solution (Figure 4). We repeated the
experiment using a batch of dissociated retinal cells instead
of whole retinas, but we did not detect AVP secretion (data
not shown).
DISCUSSION
We  examined  the  possibility  that  endogenous  AVP  is
synthesized in a certain type of retinal cell. Using AVP-eGFP
transgenic  rats,  (1)  immunohistochemistry  showed  that
endogenous AVP positive cells are present in both the GCL
and INL, (2) RT–PCR showed that endogenous AVP mRNA
is present in GFP-positive cells, and (3) whole-retina RT–PCR
showed that AVP receptors V1a and V1b are present in the
retina. These findings suggest that the retina has an intrinsic
AVP-synthesizing and -receiving mechanism that can operate
in a paracrine manner.
We did not, however, detect AVP secretion from the
retina. The endogenous AVP expression level in the wild-type
retina was probably too low to be detected. In the present
results, we detected only a faint band of endogenous AVP
mRNA  by  RT–PCR  (Figure  2).  The  band  of  endogenous
AVP mRNA was fainter than that of the transgene of AVP-
eGFP, even after 45 cycles of RT–PCR. It is possible that the
expression level of endogenous AVP is very low. However,
as no attempt at quantitative PCR has been made, the result
does not necessarily mean that the AVP expression level is
low. Moreover, the endogenous AVP expression level might
be  dynamically  regulated  by  intracellular  machinery  or
environmental  factors  in  the  retina.  In  fact,  in  the
hypothalamic AVP neurons, AVP expression was regulated
by various kinds of acute and chronic stresses such as osmotic
changes or inflammatory/nociceptive stresses [26].
The results of the present study have not clarified the
functional roles of endogenous AVP in the retina. The eye is
a rather closed environment, and in addition to its vascular
effects, AVP from retinal cells might therefore act within the
retina in a paracrine manner through V1a and V1b receptors.
Retinal endogenous AVP might have functional roles under
pathological  conditions  such  as  high  intraocular  pressure
(IOP). Injection of AVP into the anterior chamber or the
vitreous chamber caused significant reduction in IOP and
pupil size, probably due to stimulation of V1 receptors inside
the eye [13,15]. It is therefore possible that endogenous AVP
is expressed at a high level under pathological conditions such
as high IOP to regulate the pressure.
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